• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Mind Medicine (MindMed) Inc.

    5/5/25 4:06:27 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MNMD alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001813814
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Mind Medicine (MindMed) Inc.
    Jurisdiction of Incorporation/Organization
    BRITISH COLUMBIA, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Mind Medicine (MindMed) Inc.
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    New York NEW YORK 10007 212-220-6633

    3. Related Persons

    Last Name First Name Middle Name
    Barrow Robert
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Wiley Matt
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Karlin Daniel
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Liao Carrie
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sullivan Mark R.
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bruhn Suzanne
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Crystal Roger
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Krebs Andreas
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Vallone Carol A.
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gryska David
    Street Address 1 Street Address 2
    One World Trade Center Suite 8500
    City State/Province/Country ZIP/PostalCode
    New York NEW YORK 10007
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
    X Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2023-08-11    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Term loan, $7,000,000 of which is convertible into common shares.

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $7,000,000 USD
    or    Indefinite
    Total Amount Sold $7,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Term loan, $7,000,000 of which is convertible into common shares.

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    1

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Mind Medicine (MindMed) Inc. /s/ Mark R. Sullivan Mark R. Sullivan Chief Legal Officer 2025-05-05

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $MNMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MNMD

    DatePrice TargetRatingAnalyst
    1/28/2025$23.00Outperform
    Evercore ISI
    12/20/2024$20.00Buy
    Chardan Capital Markets
    10/14/2024$20.00Outperform
    Leerink Partners
    7/24/2024$36.00Buy
    ROTH MKM
    5/29/2024$27.00Outperform
    Robert W. Baird
    4/15/2024$20.00Outperform
    Leerink Partners
    12/5/2023$9.00Buy
    Canaccord Genuity
    12/9/2022$25.00Buy
    ROTH Capital
    More analyst ratings

    $MNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Announces New Employee Inducement Grants

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 121,500 common shares of the Company (the "Options"), with an effective grant date of April 21, 2025. The Options have an exercise price equal to the closing price of MindMed's common shares on April 18, 2025, the last trading day on which MindMed's common shares traded prior to the date of the grant, and will vest over a four-year period with 25% vesting on the

      4/21/25 4:01:00 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.

      10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:25:20 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/8/25 7:15:09 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form D filed by Mind Medicine (MindMed) Inc.

      D - Mind Medicine (MindMed) Inc. (0001813814) (Filer)

      5/5/25 4:06:27 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Karlin Daniel sold $46,075 worth of shares (6,836 units at $6.74), decreasing direct ownership by 2% to 446,177 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:17 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert sold $142,942 worth of shares (21,208 units at $6.74), decreasing direct ownership by 2% to 856,556 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:18 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Legal Officer Sullivan Mark sold $44,322 worth of shares (6,576 units at $6.74), decreasing direct ownership by 2% to 316,621 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      3/26/25 5:00:13 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Financials

    Live finance-specific insights

    See more

    $MNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

      --Dosed first patient in Emerge, the first Phase 3 study of MM120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD); 12-week topline data anticipated in 2H 2026-- --Enrollment on track in Phase 3 Voyage and Panorama studies of MM120 (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --Company to host a conference call today at 8:00 a.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its first quarter 2025 financial results and pro

      5/8/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, May 8, 2025 to report financial results for the first quarter ended March 31, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webca

      4/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

      --First Patients Dosed in Phase 3 Voyage and Panorama studies of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD); 12-week topline data anticipated in 1H 2026 for Voyage and 2H 2026 for Panorama-- --On track to initiate Emerge, the first Phase 3 study of MM120 ODT in Major Depressive Disorder (MDD) in 1H of 2025-- --Raised approximately $250 million in gross proceeds through two equity financings in 2024; cash and cash equivalents of $273.7 million as of December 31, 2024, expected to fund operations into 2027 and extend at least 12 months beyond the first Phase 3 topline data readout for MM120 ODT in GAD-- --Company to host a conference call today at 8:00

      3/6/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Evercore ISI initiated coverage on MindMed with a new price target

      Evercore ISI initiated coverage of MindMed with a rating of Outperform and set a new price target of $23.00

      1/28/25 7:14:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chardan Capital Markets initiated coverage on MindMed with a new price target

      Chardan Capital Markets initiated coverage of MindMed with a rating of Buy and set a new price target of $20.00

      12/20/24 7:44:37 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Leerink Partners resumed coverage on MindMed with a new price target

      Leerink Partners resumed coverage of MindMed with a rating of Outperform and set a new price target of $20.00

      10/14/24 7:36:33 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • MindMed Appoints Matt Wiley as Chief Commercial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Matt Wiley as its Chief Commercial Officer (CCO). In his new role, Mr. Wiley will serve as a member of the executive team, overseeing the Company's commercial vision and strategy as it prepares for the potential launch of its first product, MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD) and major depressive disorder (MDD). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317

      3/17/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Javier A. Muniz, M.D., as Vice President of Research and Development (R&D) Strategy. In his new role, Dr. Muniz will drive innovation and growth of MindMed's R&D operations as the Company prepares to initiate three Phase 3 studies of MM120 orally disintegrating tablet (ODT) in generalized anxiety disorder and major depressive disorder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203094211/en/Javier Muniz,

      12/3/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Committee and oversee the Company's regulatory and quality functions, as well as its product registration strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118653031/en/(Photo: Business Wire) "We are thrilled to welcome Gregg to the MindMed team. His leadership will strengthen o

      11/18/24 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/20/24 9:14:04 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

      SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      11/14/24 4:05:16 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/21/24 4:05:38 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

      SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)

      3/15/24 4:08:37 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care